David Esposito

David Esposito is the CEO of ONL Therapeutics based in Ann Arbor. ONL is developing therapeutics to protect the vision of patients with retinal disease. David is a combat veteran and experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers (Armune Bioscience sold to Exact Sciences, Phadia sold to Thermo Fisher Scientific).